Xianxin Hua's research lab at the University of Pennsylvania focuses on developing innovative immunotherapies for treating acute myeloid leukemia (AML). The lab is particularly interested in creating CAR T cells that target specific proteins on AML cells to improve treatment effectiveness while minimizing damage to healthy cells. Their work aims to translate new findings into clinical applications to offer better therapeutic options for patients with refractory AML.

Dr. Lin Z. Li's research lab focuses on developing advanced imaging techniques to enhance the prognosis of early-stage triple negative breast cancer. By using a method called Optical Redox Imaging, the lab aims to identify metabolic variations within tumors that could inform treatment strategies and improve patient outcomes. Their work is essential for creating better diagnostic tools that predict disease progression, leading to more personalized treatment approaches for cancer patients.

Dr. David Cormode's lab at the University of Pennsylvania focuses on enhancing breast cancer screening techniques using advanced materials. They are developing silver telluride nanoparticles as contrast agents for dual-energy mammography, aimed at improving tumor detection, especially in women with dense breast tissue. This research combines innovative nanoparticle technology with clinical applications to aim for better outcomes in breast cancer detection and treatment.

Dr. Qi Long's lab at the University of Pennsylvania focuses on developing artificial intelligence systems that can provide trustworthy and explainable support for clinical decision-making in healthcare. The primary goal is to improve treatment selection for patients with conditions like non-small cell lung cancer and sepsis by creating models that integrate complex medical data with clinician insights. This innovative research seeks to empower physicians with actionable and reliable explanations for AI-driven recommendations, enhancing both patient care and trust in technology.

Dr. Kevin B. Johnson's lab focuses on leveraging artificial intelligence to enhance the efficiency of clinical documentation in healthcare. The team's research aims to reduce the burden of documentation on clinicians by developing algorithms that can automate the process of summarizing patient-clinician encounters. This innovative work aims to improve healthcare delivery while addressing clinician burnout and enhancing the overall quality of patient care.

Dr. James Eberwine's lab at the University of Pennsylvania studies how individual brain cells respond to alcohol, especially in the context of Alcohol Use Disorder (AUD). They are using advanced techniques to look at changes in gene activity and chromatin structure in single neurons and astrocytes after alcohol exposure. The goal is to understand the underlying biology of AUD and identify potential therapeutic targets by analyzing these cellular responses in their natural brain environment.

Dr. Nicolai Doliba's lab at the University of Pennsylvania focuses on understanding the early cellular changes that occur in the progression of Type 1 Diabetes (T1D). The research particularly investigates how alpha cells, responsible for glucagon secretion, function in individuals at high genetic risk for T1D and how their abnormalities might influence the disease's progression. By examining cell signaling pathways and energy metabolism, the lab aims to uncover potential intervention points to delay or prevent T1D development.

Li Shen's research lab focuses on using innovative data analytic techniques to help find new treatments for Alzheimer's disease. By leveraging advanced machine learning and bioinformatics approaches, the lab aims to analyze large-scale medical data to identify promising drug candidates for repurposing. This work has the potential to improve our understanding of Alzheimer's and contribute to better clinical outcomes for affected individuals.

Dr. Gregory Bowman's lab at the University of Pennsylvania focuses on understanding the structural role of the apolipoprotein E (ApoE) protein in Alzheimer's disease. By using advanced computer simulations and experimental techniques, the lab aims to uncover the differences between harmful and protective isoforms of ApoE, which could lead to the development of new therapies for Alzheimer's. The research is crucial given the increasing prevalence of Alzheimer's disease as the population ages.

Dr. Michael Harhay's research lab focuses on improving the design and analysis of clinical trials for acute respiratory distress syndrome (ARDS), a serious condition that leads to respiratory failure. The lab employs advanced statistical methods, specifically Bayesian causal inference and machine learning, to evaluate data from numerous clinical trials. By reanalyzing existing data, the lab aims to uncover valuable insights that traditional methods may miss, ultimately helping to identify effective treatments for ARDS and understand which patient groups may benefit the most.

Dr. Montserrat C Anguera's lab at the University of Pennsylvania focuses on understanding why females are more prone to developing systemic lupus erythematosus, an autoimmune disease. The lab studies how the X-chromosome, which carries many immunity-related genes, behaves differently in female B cells, particularly under chronic inflammation conditions. By examining gene regulation processes and epigenetic changes, they aim to reveal new insights into disease mechanisms and potential therapeutic targets for lupus.

Dr. Erika L Holzbaur's lab at the University of Pennsylvania studies how organelles and proteins are transported within neurons. This transport is crucial for neuron health and function since defects in this process can lead to neurodegenerative diseases like ALS. The lab uses advanced imaging techniques to understand the mechanisms involved, especially the roles of different molecular motors and the cytoskeleton in moving organelles like mitochondria and synaptic vesicles along axons.

Dr. Sydney Shaffer's lab at the University of Pennsylvania studies Barrett's esophagus, a condition that can lead to esophageal cancer. They focus on understanding how this condition progresses from non-dysplastic to dysplastic stages, which is crucial for developing better diagnostic tools and therapies. By using advanced techniques like single-cell analysis and 3D organoid models, their research aims to uncover the molecular changes that occur during this progression and identify potential targets for intervention.

Dr. Joseph A. Baur's lab at the University of Pennsylvania focuses on understanding how the metabolism of NAD+, a crucial molecule in cellular processes, can be manipulated to enhance health, especially in contexts of aging, obesity, and heart failure. The lab investigates the effects of NAD+ on glucose metabolism, muscle mass preservation during weight loss therapies, and the benefits of NAD+ precursor supplements. They aim to uncover the biological mechanisms that can lead to better therapeutic options for metabolic disorders.

Dr. William A. Beltran’s lab focuses on understanding and treating inherited retinal diseases, which can cause blindness. They work primarily with canine models that mimic these human diseases, helping to unravel the genetic and molecular basis of conditions like retinitis pigmentosa. By developing new therapies based on their findings, they aim to improve the quality of life for patients with these previously untreatable conditions.

Dr. Frederick Bennett's lab at the University of Pennsylvania focuses on developing innovative cell therapies for neurodegenerative diseases, particularly leukodystrophies like Krabbe disease. The research aims to improve the efficacy of hematopoietic stem cell transplantation by engineering immune cells that can effectively replace damaged brain cells. By optimizing these techniques in animal models, the lab is paving the way for potential new treatments to help young patients suffering from this devastating condition.

Dr. Kara A. Bernstein's lab at the University of Pennsylvania focuses on understanding how a particular protein complex, called the Shu complex, helps repair DNA damage caused by environmental factors. They study both yeast and human cells to learn about the mechanisms of DNA repair and how disruptions in these processes can lead to cancer. By exploring these fundamental processes, the lab aims to uncover new insights that could help identify individuals at greater risk for cancer due to mutations in the genes involved.

Dr. Igor Brodsky's lab at the University of Pennsylvania focuses on how the immune system responds to infections by bacteria like Yersinia. His team studies the formation of granulomas, which are organized clusters of immune cells that help contain infections. By understanding the role of specific immune cells like inflammatory monocytes and signaling molecules such as IL-1, the lab aims to uncover mechanisms that control bacterial infections and influence public health.

The lab focuses on understanding the role of calcium transfer from the endoplasmic reticulum to mitochondria in the development and spread of pancreatic cancer. By using advanced cell and animal models, the research aims to uncover new therapeutic targets that could improve treatment outcomes for this aggressive cancer. The lab employs various techniques to investigate metabolic processes and how they relate to cancer cell survival and metastasis.

Dr. Roger A Greenberg's lab at the University of Pennsylvania focuses on understanding how cancer cells with genomic instability can stimulate immune responses. They study the interactions between damaged DNA in cancer cells and the immune system, which can affect tumor growth and immune therapy effectiveness. The lab employs a multidisciplinary approach, integrating various techniques to explore these relationships and develop new therapies for cancer.